TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06706401
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab is recommended for the following patients : Stage T1-T2/N2a-N2b and T3/N0-N1-N2a-N2b. concomitant Cetuximab is standard of care treatments and should be administered as per standard practice.~Cetuximab therapy will be started with an intravenous loading dose of 400 mg/m2 one week before start of RT followed by six (radiotherapy over 6 weeks) or seven (radiotherapy over 7 weeks) weekly doses of 250 mg/m2.
Study: NCT06704516
Drug: Menopausal hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Any brand, composition, route and dose of systemic menopausal hormone therapy containing oestrogen.~Brands of HRT include oestrogel, Evorel, Lenzetto, Estradot, Progynova (this list is not exhaustive)
Study: NCT06706232
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sequential administrations of 25 mg psilocybin, 4 weeks apart.
Study: NCT06705088
Drug: SUVN-I6107
Normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUVN-I6107 Tablet
Study: NCT04750616
Drug: Niacinamide
Normalized name: Niacinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Niacinamide 3 grams on the day of surgery and post-surgical days one and two
Study: NCT01419366
Drug: Torrent's Donepezil Hydrochloride Tablets 10mg
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06346340
Drug: Miebo
Normalized name: Miebo
DrugBank: Perfluorohexyloctane (DB17823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.
Study: NCT05632133
Drug: Lacosamide 50 MG Oral Tablet
Normalized name: LACOSAMIDE 50 mg ORAL TABLET
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.
Study: NCT05843968
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 doses of rituximab 375 mg/m\^2(maximum 500mg/day) at 6 months intervals.~Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection.
Study: NCT05843968
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year.~Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks
Study: NCT05359263
Drug: Dapagliflozin 10 mg
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention arm consists of dapagliflozin 10 mg orally once daily
Study: NCT04925414
Drug: oxygenotherapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High concentration mask delivering 15L/min of oxygen
Study: NCT04925414
Drug: placebo air aerosol
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration mask delivering 15L/min of air
Study: NCT05490953
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated pentoxifylline during the first two chemotherapy cycles of their respective treatment.
Study: NCT05924100
Drug: Luspatercept Injection [Reblozyl]
Normalized name: luspatercept Injection [Reblozyl]
DrugBank: Luspatercept (DB12281)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg).~All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit.
Study: NCT05870501
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5mg/kg IV infusion
Study: NCT05870501
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.045mg/kg IV infusion
Study: NCT05655221
Drug: B1344
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)
Study: NCT06080100
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation of xenon in a sub-narcotic dosage
Study: NCT05764798
Drug: Experimental group: Shugan Jieyu Capsule combined with zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shugan Jieyu capsule and zolpidem orally for 8 consecutive weeks
Study: NCT05764798
Drug: Control group: Placebo combined with zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo and zolpidem orally for 8 consecutive weeks
Study: NCT04983940
Drug: Jatenzo
Normalized name: Jatenzo
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 237 mg soft gel capsule taken twice a day by mouth with food.
Study: NCT05117710
Drug: Ebselen
Normalized name: Ebselen
DrugBank: Ebselen (DB12610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebselen is an organoselenium compound, developed originally as an antioxidant for use in neuroprotection, post-stroke. Ebselen is a bioavailable and brain penetrant inhibitor of inositol monophosphatase (IMPase) (Ki ≈ 1 μM).
Study: NCT06393517
Drug: PF-06954522 IR (Formulation 1)
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
Study: NCT06393517
Drug: PF-06954522 MR (Formulation 2)
Normalized name: chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Study: NCT06393517
Drug: PF-06954522 MR (Formulation 3)
Normalized name: hypromellose
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 3 by mouth
Study: NCT06079476
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-use prefilled syringe for SC injection.
Study: NCT04935879
Drug: Inclacumab
Normalized name: Inclacumab
DrugBank: Inclacumab (DB12246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.
Study: NCT06513364
Drug: WH002
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A（ddWH002-ddEC）： Regimen for Group A during Cycles 1-Cycles 4:WH002， 260 mg/m² administered intravenously on Day 1, with a cycle length of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group A during Cycles 5-Cycles 8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with each cycle lasting 2 weeks (Q2W), continued for 4 consecutive cycles.
Study: NCT06513364
Drug: paclitaxel injection
Normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group B (ddP-ddEC):~Regimen for Group B during Cycles C1-C4:~• Paclitaxel Injection (Paclitaxel®) 175 mg/m², administered intravenously on Day 1, with a cycle duration of 2 weeks (Q2W), repeated for a total of 4 cycles.~Regimen for Group B during Cycles C5-C8:~• Epirubicin Hydrochloride 90 mg/m² and Cyclophosphamide for Injection 600 mg/m², both administered intravenously on Day 1, with cycles recurring every 2 weeks (Q2W), for a series of 4 cycles.
Study: NCT06030895
Drug: Sorafenib Tablets
Normalized name: Sorafenib Tablets
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib Tablets (200 -400 mg) twice daily
Study: NCT06717243
Drug: Carboplatin/Cisplatin -Etoposide - Atezolizumab
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis.
Study: NCT06710288
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose: 800 mg/m2 intravenously (IV) Frequency: administered on Day 1, Day 8, and Day 15 of each cycle (every 4 weeks)
Study: NCT06716307
Drug: CagriSema (cagrilintide B and semaglutide I)
Normalized name: CagriSema component Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.
Study: NCT06716307
Drug: CagriSema A
Normalized name: CagriSema component Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.
Study: NCT06715462
Drug: N0750
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N0750 caps + Cymbalta placebo caps + Lyrica placebo caps
Study: NCT06716645
Drug: Robitussin Maximum Strength Nighttime Cough DM
Normalized name: DEXTROMETHORPHAN HYDROBROMIDE 30 mg in 20 mL / DOXYLAMINE SUCCINATE 12.5 mg in 20 mL ORAL SOLUTION [Robitussin Maximum Strength Nighttime Cough DM]
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg
Study: NCT06713590
Drug: Axatilimab
Normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axatilimab will be administered at protocol defined dose.
Study: NCT06715709
Drug: Dexamethasone IV
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexamethasone administered intraoperatively at the time of anesthesia. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus.
Study: NCT06715709
Drug: Dexamethasone IV+Oral
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexamethasone administered intraoperatively and on the morning of the first postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
Study: NCT06715709
Drug: Dexamethasone IV+Oral 2 Day
Normalized name: dexamethasone 2 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive dexamethasone administered intraoperatively, the morning of the first postoperative day, and the morning of the second postoperative day. The dose of dexamethasone will be 16mg intravenous (IV) if you do not have a prior diagnosis of diabetes mellitus, or 8mg IV if you do have a previous diagnosis of diabetes mellitus. The medication will be intravenously administered while inpatient, and via oral route when discharged.
Study: NCT06719011
Drug: Cagrilintide B
Normalized name: Cagrilintide
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive Cagrilintide B administered as subcutaneous (s.c. under the skin) injection.~Single ascending dose (SAD) will be injected for Part A cohorts and multiple ascending doses (MAD) will be injected for Part B cohorts.
Study: NCT06717425
Drug: PF-07976016
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken once daily
Study: NCT06718686
Drug: Rifaximin SSD 40 mg IR tablet
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug therapy vs placebo
Study: NCT06718413
Drug: hyaluronidase plus saline
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Injection of study drug with saline
Study: NCT06718413
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injection of normal saline and no study drug
Study: NCT06718634
Drug: BL-M08D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06715085
Drug: Plasma Rich in Growth Factors (PRGF)
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.
Study: NCT06718257
Drug: Gemcitabine combined with cisplatin or oxaliplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
Study: NCT06718933
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADC
Study: NCT06718933
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab biosimilar
Study: NCT06718933
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-HER2 inhibitor
Study: NCT06717698
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide will be administered subcutaneously.
Study: NCT06710223
Drug: SD-101
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toll-like receptor 9 (TLR9) agonist
Study: NCT06710223
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CTLA4
Study: NCT06710223
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PDL1
Study: NCT06721910
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Blockade of the interleukin-6 receptor
Study: NCT04891250
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of SARS Cov-2 patients with Ivermectin
Study: NCT04730037
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: - Edoxaban 30 mg/60 mg tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
Study: NCT04730037
Drug: Warfarin Potassium
Normalized name: warfarin potassium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Warfarin K 1 mg tablets once daily (Dose adjusted with target PT-INR of 1.5-2.5)
Study: NCT04730037
Drug: Warfarin Potassium placebo
Normalized name: warfarin potassium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Warfarin K 1 mg placebo tablets once daily
Study: NCT04730037
Drug: Edoxaban placebo
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: - Edoxaban 30 mg/60 mg placebo tablet according to body weight. 60 kg or less: 30 mg once daily, over 60 kg: 60 mg once daily, reduced to 30 mg once daily depending on renal function and concomitant medications
Study: NCT05793060
Drug: Dexmedetomidine Hydrochloride
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 50 Mcg
Study: NCT05793060
Drug: Dexamethasone Phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 4 mg
Study: NCT06500273
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for lymphodepletion
Study: NCT04503694
Drug: Nivolumab 10 MG/ML Intravenous Solution
Normalized name: nivolumab 10 mg/mL intravenous solution
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given at a dose of 240 mg during the pre-operative phase only as indicated below:~* On day 1 and 15, during the Induction treatment~* On day 29, 43 and 57, during the Consolidation treatment
Study: NCT04503694
Drug: Regorafenib 30 MG Oral Tablet
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib will be administered orally once a day at a dose of 60 mg/day (2 tablets of 40 mg), during the pre-operative phase only as indicated below:~* From day 1 to 14, during the Induction treatment~* From day 29 to 49, during the Consolidation treatment
Study: NCT06550882
Drug: OBIZUR
Normalized name: Obizur
DrugBank: Susoctocog alfa (DB11606)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: OBIZUR injection.
Study: NCT05578456
Drug: Prednisone and Aspirin
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone 10 mg and aspirin 75-100mg per day per os
Study: NCT00002195
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00002195
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002195
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06722430
Drug: Itraconazole (ITZ)
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05082571
Drug: vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vadadustat tablet orally once a day for 52 weeks
Study: NCT06723665
Drug: 18F-PSMA-1007
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-PSMA-1007 is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
Study: NCT06723665
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg
Study: NCT06723691
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin
Study: NCT06723691
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin
Study: NCT06723691
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin
Study: NCT06723691
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin
Study: NCT06703255
Drug: HX301+/Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each.
Study: NCT06701812
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
Study: NCT04873375
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
Study: NCT06080256
Drug: Alirocumab
Normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: alirocumab (75 mg every 2 weeks)
Study: NCT06080256
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20-40mg